Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Kronos Bio, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
KRON
Nasdaq
2836
www.kronosbio.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Kronos Bio, Inc.
We Think Kronos Bio (NASDAQ:KRON) Needs To Drive Business Growth Carefully
- Jan 13th, 2025 10:51 am
Discover 3 US Penny Stocks With Market Caps Over $40M
- Dec 3rd, 2024 1:04 pm
Kronos Bio announces interim CEO and workforce cuts of 83%
- Nov 28th, 2024 4:50 pm
Kronos Bio Shakes Up Leadership - Cuts 83% Of Workforce Amid Strategic Overhaul
- Nov 27th, 2024 1:59 pm
Kronos Bio Announces CEO Transition and Reduction in Force
- Nov 27th, 2024 12:30 pm
Kronos, Idorsia plan layoffs; PTC shelves ALS drug
- Nov 27th, 2024 10:38 am
Kronos Bio Third Quarter 2024 Earnings: Beats Expectations
- Nov 16th, 2024 12:27 pm
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024
- Nov 14th, 2024 9:02 pm
Kronos mulls ‘strategic alternatives’ after axing cancer drug development
- Nov 14th, 2024 6:24 pm
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Tops Revenue Estimates
- Nov 13th, 2024 10:30 pm
Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives
- Nov 13th, 2024 9:05 pm
Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma
- Nov 5th, 2024 2:00 pm
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors
- Oct 23rd, 2024 12:55 pm
Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors
- Oct 9th, 2024 12:55 pm
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease
- Oct 7th, 2024 12:55 pm
Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy
- Sep 25th, 2024 12:55 pm
Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer
- Sep 23rd, 2024 12:55 pm
After Plunging -5.53% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON)
- Sep 10th, 2024 1:35 pm
Kronos Bio Announces Participation in Medical and Investor Conferences in September
- Sep 3rd, 2024 12:55 pm
After Plunging -23.49% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON)
- Aug 22nd, 2024 1:35 pm
Scroll